Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 11.02.2021.

#biotechnology
#lifesciences
#pharmaceuticals
#biospace
#clinicaltrials
#COVID
#treatment
#vaccine
#COVID19
#coronavirus

Companies And Industries

@Biotechnology shared
On Feb 8, 2021
SEC Slaps Biotech Consultant Mark Ahn with Insider Trading Charges https://t.co/FAch36AxLY https://t.co/xLzBwlNbb7
Open
SEC Slaps Biotech Consultant Mark Ahn with Insider Trading Charges

SEC Slaps Biotech Consultant Mark Ahn with Insider Trading Charges

A Portland, Oregon biotech consultant is facing two counts of insider trading charges, with federal prosecutors and securities regulators claiming the defendant made profitable stock trades ...

@BiotechWorld shared
On Feb 8, 2021
Avrobio gene therapy eliminates toxic substrate in Fabry patient https://t.co/oc8JTvxmE8 https://t.co/ULiD3QmAZ3
Open
Avrobio gene therapy eliminates toxic substrate in Fabry patient

Avrobio gene therapy eliminates toxic substrate in Fabry patient

The first Fabry disease patient treated with Avrobio’s plato gene therapy platform in a phase 2 trial has experienced the complete clearance of toxic kidney substrate. 

@biospace shared
On Feb 9, 2021
2021 Biopharma Update on the Novel Coronavirus: February 9 #biospace #lifesciences #biotechnology #pharmaceuticals #clinicaltrials #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine https://t.co/FnlJiDovCt
Open
2021 Biopharma Update on the Novel Coronavirus: February 9

2021 Biopharma Update on the Novel Coronavirus: February 9

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.

@IAmBiotech shared
On Feb 5, 2021
#GoodDayBIO: A pandemic milestone worth cheering: more people have gotten at least one dose of a COVID-19 vaccine than have tested positive for the virus. Plus, a big cheer for biotech as we indulge in our favorite Super Bowl snacks this weekend. https://t.co/sx7sb1ZknG
Open
Cheering biotech breakthroughs, from vaccines to Super Bowl snacks | BIO

Cheering biotech breakthroughs, from vaccines to Super Bowl snacks | BIO

Super Bowl Sunday is upon us—but today, we’re cheering for biotechnology breakthroughs that are ensuring the resiliency of our food supply and changing the course of the pandemic (plus a ...

@BioWorld shared
On Feb 5, 2021
Lucky seven: Biotech IPOs set a single-day record https://t.co/7NMhwOXKZL
Open
Lucky seven: Biotech IPOs set a single-day record

Lucky seven: Biotech IPOs set a single-day record

The week finished with flurry of biotech IPOs, seven of them, a record number in a single day, according to BioWorld stats. Last year was a record year for IPOs as 106 new offerings were ...

@biospace shared
On Feb 5, 2021
@JNJNews Sends One-Shot Vaccine to @US_FDA Emergency Use Authorization Expected End of February #biospace #lifesciences #biotechnology #pharmaceuticals #clinicaltrials #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine https://t.co/LqNqHuy3KA
Open
J&J Sends One-Shot Vaccine to FDA, Emergency Use Authorization Expected End of February

J&J Sends One-Shot Vaccine to FDA, Emergency Use Authorization Expected End of February

Johnson & Johnson’s Janssen Biotech submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) for its single-dose COVID-19 vaccine.

@NatureBiotech shared
On Feb 9, 2021
@physorg_com Hebrew U. research replaces biopsies with simple blood tests #NBTintheNews via @Jerusalem_Post https://t.co/0JLnwaXAxm
Open
@FierceBiotech shared
On Feb 8, 2021
He will take over from Ken Takeshita, M.D., the company’s global head of clinical development, who will leave at the end of February to “pursue another opportunity” https://t.co/uilxpZm6Cb
Open
Gilead's Kite unit snags ex-bluebird cancer research head after a stopover at Verastem

Gilead's Kite unit snags ex-bluebird cancer research head after a stopover at Verastem

After a quick pit stop at Verastem Oncology, Frank Neumann, M.D., Ph.D. has landed at Gilead’s Kite Pharma, where he will lead clinical development in blood cancers and solid tumors. His ...